Premium
P3–264: Separation of drug effect from placebo control in Alzheimer's disease trials: Improving the chances
Author(s) -
Miller David,
Young Amanda,
Samuelson Priscilla,
Henley David,
Sethuraman Gopalan,
Sundell Karen
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.1338
Subject(s) - placebo , clinical endpoint , clinical trial , medicine , reliability (semiconductor) , disease , drug , separation (statistics) , drug trial , psychology , physical therapy , psychiatry , alternative medicine , computer science , machine learning , pathology , power (physics) , physics , quantum mechanics
Patients with MCI COPM mean overall ratings Performance (max 10)*1,*2 4.6 (1.82) 5.7 (1.35) 5.9 (1.26) Satisfaction (max 10)*1,*2 5.2 (1.39) 6.1 (1.55) 6.3 (1.46) ADAS-K-Cog (max 70) 10.2 (3.55) 9.8 (4.98) 9.6 (4.88) MMSE-KC (max 30) 24.9 2.34) 24.8 (3.19) 24.8 (2.48) S-IADL Performance (max 45) 13.7 (4.88) 11.2 (5.98) 13.6 (4.86) Potential (max 45) 11.3 (4.74) 9.5 (5.70) 10.6 (5.95) QOL-AD(self) (max 52) 30.4 (4.97) 32.3 (5.52) 32.2 (6.19) QOL-AD(family) (max 52) 30.9 (3.45) 33.2 (5.36) 32.9 (6.61) GDS-kr (max 30)*1 12.5 (7.49) 9.8 (5.21) 11.1 (7.41) Family carers Burden Index (max 88) 20.8 ( 6.48) 23.0 (10.14) 21.7 (13.61) CES-D (max 60) 13.3 (14.70) 12.0 (16.06) 11.8 (11.98)